Depomed swings to $1.4M Q3 profit Oct 30, 2009
Depomed swings to $1 ... Depomed swings to $1 ... Menlo Park-based Depomed (NASDAQ:DEPO) had revenue of $23 million, compared to $14. (San Jose Business Journal, CA)
Depomed Shares Plunge on Disappointing Trials for Hot Flash Drug Oct 13, 2009
Depomed Inc. (DEPO) announced that its drug Serada, which is used to treat hot flashes brought on by menopause and is in the Phase 3 of clinical trials, showed disappointing results ... Shares of Depomed plunged 37. (Fox News)
Depomed Says Shingles Pain Drug Meets Study Goal Oct 6, 2009
Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year high ... Depomed Inc. on Monday reported a successful late stage clinical trial of a drug intended to treat pain following the viral infection shingles, and its shares soared on the news ... Depomed said it plans to file for Food and Drug Administration approval by the end of March 2010, and in morning trading, its shares surged to a three-year high. (ABC News -- Wire)
Depomed swings to $9.6M Q2 loss Jul 31, 2009
Depomed swings to $9 ... Depomed swings to $9 ... Menlo Park-based Depomed (NASDAQ:DEPO) said last year's profit was primarily attributable to a one-time gain of $7. (San Jose Business Journal, CA)
Depomed to receive $10M in Merck license deal Jul 23, 2009
Menlo Park-based Depomed (NASDAQ:DEPO) said the license involves metformin extended release technology, a potential therapy for type II diabetes. Depomed is eligible to receive a milestone payment upon filing of the New Drug Application for the therapeutic candidate, as well as royalties on any net product sales for an agreed-upon period ... Merck will also be granted a right of reference to the New Drug Application covering Depomed s Glumetza diabetes drug. (San Jose Business Journal, CA)
Depomed Q1 loss widens on greater revenue May 5, 2009
Menlo Park-based Depomed (NASDAQ:DEPO) had $9. 9 million in revenue, compared to $5. (San Jose Business Journal, CA)
